SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025
Rhea-AI Summary
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will conduct a fireside chat on August 12, 2025, at 3:00 PM ET.
Investors can access the presentation through a webcast by registering online, and the live audio will be available on the company's website investor section. The webcast recording will remain accessible for replay for at least 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SIBN declined 0.11%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, August 12, 2025, at 12:00 p.m. Pacific Time/03:00 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://wsw.com/webcast/canaccord108/sibn/2510356. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System®, SI-BONE has supported over 4,600 physicians in performing a total of over 125,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies with over 175 peer reviewed publications including four randomized controlled trials. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma.
For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.
SI-BONE, Sacropelvic Solutions, iFuse Implant System®, iFuse Bedrock Granite, and iFuse TORQ, are registered trademarks, and iFuse 3D, iFuse TORQ TNT, and iFuse INTRA are trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved.
Investor Contact: Saqib Iqbal investors@si-bone.com
FAQ
When is SI-BONE (SIBN) presenting at the Canaccord Genuity Growth Conference 2025?
How can investors access SI-BONE's (SIBN) Canaccord conference presentation?
How long will SI-BONE's (SIBN) Canaccord conference presentation be available for replay?
What does SI-BONE (SIBN) specialize in as a company?
